ZNTL - Gain Therapeutics inks multi-target drug discovery collaboration agreement with zentalis

Gain Therapeutics ([[GANX]]) announces a multi-target collaboration agreement with Zentalis Pharmaceuticals ([[ZNTL]] -0.7%) to discover new product candidates for the treatment of cancer.Under the terms of the agreement, Gain will pursue binding site identification on target proteins that will be selected and agreed upon by both parties.Selected compounds will be tested in the lab by Zentalis against the target protein to confirm binding and action to identify and characterize novel compounds for development.Gain will use its proprietary SEE-Tx computational platform technology to identify new sites on target proteins for potential use in oncology.

For further details see:

Gain Therapeutics inks multi-target drug discovery collaboration agreement with zentalis